% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Eichhorn:303378,
      author       = {M. E. Eichhorn and B. Niedermaier and P. Charoentong$^*$
                      and L. V. Klotz and P. Baum and R. Griffo and M. Allgäuer
                      and A. Stenzinger and H. Bischoff and M. A. Schneider and P.
                      Christopoulos and U. Haberkorn and C.-P. Heußel and R.
                      Savai and M. P. Roberti$^*$ and I. Zoernig$^*$ and D.
                      Jäger$^*$ and F. Herth and M. Thomas and H. Winter and F.
                      Eichhorn},
      title        = {{N}eoadjuvant anti-programmed death-1 immunotherapy by
                      pembrolizumab in resectable non-small cell lung cancer:
                      results of the {NEOMUN} trial.},
      journal      = {Journal for ImmunoTherapy of Cancer},
      volume       = {13},
      number       = {8},
      issn         = {2051-1426},
      address      = {London},
      publisher    = {BioMed Central},
      reportid     = {DKFZ-2025-01627},
      pages        = {e011874},
      year         = {2025},
      abstract     = {The phase II NEOMUN trial was conducted to investigate the
                      therapeutic effect of preoperative programmed death
                      receptor-1 inhibitor pembrolizumab for treating non-small
                      cell lung cancer (NSCLC). Herein, we report the final
                      efficacy, safety, and long-term survival results.Patients
                      with resectable stage II/IIIA NSCLC were included. Two
                      cycles of pembrolizumab (200 mg intravenously once every 3
                      weeks) were administered before surgery. The primary
                      objectives were to assess the feasibility and safety of
                      neoadjuvant treatment and evaluate antitumor activity. We
                      analyzed the clinical parameters and pathologic,
                      radiological, and metabolic tumor response data.29 patients
                      with NSCLC were enrolled. NSCLC histology revealed
                      adenocarcinoma and squamous cell carcinoma in 24 and in 5
                      patients, respectively. $93.1\%$ of patients were treated
                      with two therapy cycles. 73 adverse events were reported, of
                      which 18 were treatment-related. Complete tumor resection
                      rate was $100\%.$ Major $(≤10\%$ vital tumor cells) and
                      complete pathologic response rates were $24.1\%$ and
                      $13.8\%,$ respectively. Tumor response increased with higher
                      programmed death-ligand 1 tumor proportion scores (TPS) and
                      high pretherapeutic tumor mutational burden (≥10 mut./Mb).
                      The metabolic response, quantified non-invasively using
                      positron emission tomography/CT, predicted the pathologic
                      tumor response. The disease-free survival was $75.9\%$ at 24
                      and 36 months, and the overall survival was $82.7\%$ at 24
                      and 36 months.Neoadjuvant immunotherapy with pembrolizumab
                      appears safe and feasible and is associated with a
                      remarkable major pathologic response rate. Preoperative TPS,
                      change in maximal standardized uptake value during the
                      induction phase, and high mutational burden might be
                      suitable clinical parameters for predicting pathologic
                      response in surgical candidates.NCT0319746.},
      keywords     = {Humans / Antibodies, Monoclonal, Humanized: therapeutic use
                      / Antibodies, Monoclonal, Humanized: pharmacology /
                      Carcinoma, Non-Small-Cell Lung: drug therapy / Carcinoma,
                      Non-Small-Cell Lung: pathology / Carcinoma, Non-Small-Cell
                      Lung: mortality / Male / Female / Middle Aged / Aged / Lung
                      Neoplasms: drug therapy / Lung Neoplasms: pathology /
                      Neoadjuvant Therapy: methods / Adult / Programmed Cell Death
                      1 Receptor: antagonists $\&$ inhibitors / Immunotherapy:
                      methods / Immune Checkpoint Inhibitors: therapeutic use /
                      Immune Checkpoint Inhibitors: pharmacology / Antineoplastic
                      Agents, Immunological: therapeutic use / Antineoplastic
                      Agents, Immunological: pharmacology / Biomarker (Other) /
                      Immune Checkpoint Inhibitor (Other) / Major pathologic
                      response - MPR (Other) / Neoadjuvant (Other) / Non-Small
                      Cell Lung Cancer (Other) / pembrolizumab (NLM Chemicals) /
                      Antibodies, Monoclonal, Humanized (NLM Chemicals) /
                      Programmed Cell Death 1 Receptor (NLM Chemicals) / Immune
                      Checkpoint Inhibitors (NLM Chemicals) / Antineoplastic
                      Agents, Immunological (NLM Chemicals)},
      cin          = {D120},
      ddc          = {610},
      cid          = {I:(DE-He78)D120-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40759442},
      doi          = {10.1136/jitc-2025-011874},
      url          = {https://inrepo02.dkfz.de/record/303378},
}